Boc-His(Boc)-ol | 167421-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Boc-His(Boc)-ol
• 英文别名: N,N'-di-Boc-histidinol；N,N'-di-Boc-(S)-histidinol；tert-butyl 4-[(2S)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]imidazole-1-carboxylate
• CAS: 167421-88-7
• 化学式: C₁₆H₂₇N₃O₅
• 分子量: 341.407
• InChiKey: NCLXJZAPMZRIDJ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Boc-His(Boc)-ol 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Conversion of chiral amino acids to enantiomerically pure α-methylamines

  摘要：

  Enantiomerically enriched alpha-methylamines are obtained in high yield by Raney nickel reduction of N-Boc-protected, amino acid-derived thioethers.

  DOI：

  10.1016/0040-4039(95)00039-f
• 作为产物：
  描述：

  N,N'-二叔丁氧羰基-L-组氨酸 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 以93%的产率得到Boc-His(Boc)-ol
  参考文献：
  名称：

  Conversion of chiral amino acids to enantiomerically pure α-methylamines

  摘要：

  Enantiomerically enriched alpha-methylamines are obtained in high yield by Raney nickel reduction of N-Boc-protected, amino acid-derived thioethers.

  DOI：

  10.1016/0040-4039(95)00039-f

文献信息

• Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases
  作者：Andrew K. Forrest、Richard L. Jarvest、Lucy M. Mensah、Peter J. O'Hanlon、Andrew J. Pope、Robert J. Sheppard

  DOI：10.1016/s0960-894x(00)00360-7

  日期：2000.8

  histidine and threonine, have been prepared and tested as inhibitors of their cognate Staphylococcus aureus aminoacyl tRNA synthetases. The arginyl derivatives were both potent nanomolar inhibitors of the Class I arginyl tRNA synthetase whereas for the Class II histidyl and threonyl tRNA synthetases, the acyl sulfamates were potent inhibitors but the adenylates had very little affinity.

  制备了精氨酸，组氨酸和苏氨酸衍生的氨基烷基腺苷酸和氨基酰基氨基磺酸盐，并对其同源金黄色葡萄球菌氨基酰基tRNA合成酶的抑制剂进行了测试。精氨酰基衍生物都是I类精氨酰基tRNA合成酶的有效纳摩尔抑制剂，而对于II类组氨酸和苏氨酰基tRNA合成酶而言，酰基氨基磺酸盐是有效的抑制剂，但腺苷酸的亲和力很小。
• PRODRUGS OF GUANFACINE
  申请人：Whomsley Rhys

  公开号：US20120065152A1

  公开（公告）日：2012-03-15

  Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration are provided herein.

  本文提供了瓜那非的前药、含有这种前药的药物组合物，以及一种利用瓜那非前药在治疗注意力缺陷多动障碍/反抗性违抗障碍（ADHD/ODD）中提供治疗益处的方法。此外，本文还提供了改善瓜那非的药代动力学或减少或避免与瓜那非给药相关的不良胃肠副作用的方法。
• [EN] COMPOSITIONS FOR CONJUGATING OLIGONUCLEOTIDES AND CARBOHYDRATES<br/>[FR] COMPOSITIONS POUR CONJUGUER DES OLIGONUCLÉOTIDES ET DES GLUCIDES
  申请人：ONEGLOBE HOLDINGS LTD

  公开号：WO2022175749A1

  公开（公告）日：2022-08-25

  The invention provides novel compositions and linking configurations for an oligonucleotide to be conjugated to a ligand for targeted in vivo delivery of an oligonucleotide. The invention further provides use of the resulting compounds and pharmaceutical compositions thereof in preparation of a medicament effective for treating a disease or condition.

  本发明提供了一种新型的寡核苷酸与配体的连接构型，用于将寡核苷酸与配体结合，以进行靶向体内传递。此外，本发明还提供了所得化合物的用途以及制备其药物组合物，以治疗疾病或病况的有效药物。
• NOVEL COMPOSITIONS FOR CONJUGATING OLIGONUCLEOTIDES AND CARBOHYDRATES
  申请人：[en]1GLOBE HEALTH INSTITUTE, NANJING

  公开号：WO2024040531A1

  公开（公告）日：2024-02-29

  The invention provides compositions and linking configurations for an oligonucleotide to be conjugated to a carbohydrate ligand for targeted in vivo delivery of an oligonucleotide. These ligand-conjugated compounds target one or more organs or cell types, e.g., the parenchymal cells of the liver that facilitate endocytic uptake. The compound has structural formula (S-HG1): R206-[A1]a-[A2]b-[A3]c-R205(S-HG1) R205, R206are each independently for each occurrence H, OH, a protecting group for OH, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, -OP(M')(M")O-nucleoside, - OP(M')(M")O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, -O- nucleotide, a nucleoside, -OP(M')( M")OR201-OP(M'")(M"")O- oligonucleotide, or an oligonucleotide; M', M", M'" and M"" are each independently for each occurrence O or S; Al, A2 and A3 are each independently for each occurrence selected from (S-1H) or (S-1G).